3/25/2011

European regulators approved Eisai's injectable drug Halaven to treat certain breast cancer patients who have received at least two chemotherapy regimens. The treatment is based on a sea sponge that is thought to inhibit growth of cancer cells.

Full Story:
InPharm.com

Related Summaries